T cells are pivotal mediators of the adaptive immune response, with cytotoxic CD8+ T lymphocytes recognising peptides displayed by MHC class I molecules. This antigen presentation process involves the ...
ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE ® SL Self-Loading MHC Class I Monomers. The novel reagents for antigen-specific CD8+ T ...
A CAR-T cell product can contain both CAR-T cells and CAR-negative bystander T cells (left). After treatment with CAR-T cell therapy, CAR-T cells kill tumor cells and release a panel of cytokines. In ...
Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...
Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...
A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...
Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results